Trinity Delta Lighthouse: Futura Medical
Trinity Delta view: The analysis of the FM57 data shows a remarkably consistent outcomes across all treatment groups and supports the view that MED3000 is an effective and safe therapy for ED. Regulatory submissions for approval of MED3000 as a medical device opens a potentially faster route to market, with probably no further clinical work required for Europe and (possibly) a small study for the US. Although difficult to compare without direct trials, the efficacy seen would suggest an activity approaching that of oral PDE5s such as tadalafil (Cialis), but with a faster onset of action and fewer side-effects. As we highlighted previously, significant unknowns remain, but the outlook is increasingly positive. We suspended our forecasts and valuation at the time of the top line FM57 results and aim to reinstate them as soon as practicable.Futura Medical is engaged in the research and development of pharmaceutical drugs and medical devices and their commercial exploitation. Co. focuses on developing products primarily for the consumer healthcare market. Co.'s focus is on sexual healthcare and pain relief. DermaSys® is Co.'s transdermal technology platform, for the absorption of active molecules through the skin. DermaSys® includes MED2002, a topical gel for the treatment of erectile dysfunction; TPR100, a topical diclofenac pain relief gel; TIB200, a topical ibuprofen pain relief gel; and SPR300, a topical methyl salicylate pain relief gel.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.